---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-100131"
form_type: "8-K"
ticker: "ARTV"
cik: "0001817241"
company_name: "Artiva Biotherapeutics, Inc."
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T16:54:48.997837+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Artiva reports FY2025 net loss of $83.9M; cash $108M into Q2 2027

## Summary
- Net loss $83.9M vs $65.4M in 2024; R&D spend $69.5M (up 38% YoY); revenue zero.
- Cash, equivalents and investments $108.0M as of Dec 31, 2025, expected to fund operations into Q2 2027.
- AlloNK for refractory RA: initial clinical response data from ≥15 patients expected H1 2026; FDA Fast Track granted.
- Planned FDA interaction in H1 2026 to discuss potential pivotal trial design for AlloNK in refractory RA.
- Appointed Subhashis Banerjee, M.D. as CMO and Thad Huston as CFO; added two board members with immunology/commercial expertise.

## SEC filing metadata
- accession: 0001193125-26-100131
- form_type: 8-K
- ticker: ARTV
- cik: 0001817241
- company_name: Artiva Biotherapeutics, Inc.
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817241/000119312526100131/0001193125-26-100131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817241/000119312526100131/artv-20260310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-100131
- JSON: https://secwatch.observer/filing/0001193125-26-100131.json
- Plain text: https://secwatch.observer/filing/0001193125-26-100131.txt

## Key facts
- Earnings Releases
  Artiva Biotherapeutics, Inc. reported the year ended December 31, 2025 results: revenue zero, net income Net loss totaled $83.9 million.
  - Period: the year ended December 31, 2025
  - Revenue: zero
  - Net income: Net loss totaled $83.9 million
  - Result: reported results
  source text: On March 10, 2026, Artiva Biotherapeutics, Inc. (“Artiva”) issued a press release announcing its financial results for the year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817241/000119312526100131/0001193125-26-100131-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.